Across TCGA pan-cancer cohorts, GPAT3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GPAT3 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GPAT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPAT3 expression acts as an unfavorable survival marker.
UCEC are the cancer types where GPAT3 Mutation most reproducibly stratifies survival.